From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

BAA – Clinical Assays for Ebola, Anthrax and Melioidosis

by Global Biodefense Staff
March 18, 2015

The DHS Directorate of Science and Technology (S&T) is seeking performers for clinical assay development against high priority pathogens.

The effort supports the Chemical and Biological Defense Division (CBD) mission of the DHS S&T to reduce the probability and potential consequences of a biological pathogen or a chemical attack on the nation’s civilian population, its infrastructure, or its agricultural system.

Specific elements of the major task areas will include:

  • Test and evaluation of in-house clinical assays specific for the detection of Ebola virus antigen, Bacillus anthracis antigen, and Burkholderia spp. Creation and characterization of novel monoclonal antibodies specifically recognizing these agents should already be completed to properly address this task.
  • Demonstrated ability to support test, evaluation, and validation studies in the performer’s laboratories. This task will involve the laboratory testing of clinical samples and materials for the detection of the specific agents described.
  • Ability to manufacture the assays using the in house reagents into lateral flow assays or suspension bead-based assay chemistries.
  • Production of reagents and assembly of reagents for test kits to support test, evaluation, and validation studies.
  • Ability to work with select agents for live testing to assess the functionality of each assay alone (Lateral Flow Assay (LFA)) and in combination with other agents in the case of bead-based assays should also be possible if the prototype assays are deemed to be functional.
  • For Ebola virus, the use of analogues and recombinant alternatives will be judged on an individual basis. However, testing against live BSL-4 agent in clinical samples will be required later in the process; how this will be accomplished should be addressed somewhere in the proposal.
  • Conduct appropriate studies to support reagent stability and test sample stability for test and evaluation studies.
  • Development of IDA 510K package for FDA approval for in vitro diagnostics.

Although subject to official fiscal appropriation and availability, it is anticipated that approximately $900,000.00 of Fiscal Year 2015 funds will be available for any resultant awards under this BAA Call.

Further details are available via Solicitation Number: HSHQDC14RB00090BAA14003Call7. Responses are due March 31, 2015.

From Our Partners
Tags: AnthraxBAABioterrorismBurkholderiaChemical DetectionEbolaEmerging Threats

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC